善恩康AKK PROBIO菌

Search documents
聚焦AKK菌免疫调节潜力,善恩康研究再拓多维保护机制
Jiang Nan Shi Bao· 2025-07-23 11:21
Core Insights - The Akkermansia muciniphila (AKK) bacterium has been recognized for its significant role in immune regulation, as evidenced by multiple studies published in top-tier journals like Science and Immunity [1][2][6] - AKK's mechanisms include triggering anti-inflammatory T cells, downregulating pro-inflammatory cytokines, and enhancing gut barrier integrity, which collectively contribute to reducing immune-related diseases [1][4][6] Group 1: Scientific Validation - AKK has been shown to enhance the efficacy of PD-1 inhibitors in cancer therapy, particularly in patients lacking AKK, where supplementation or fecal microbiota transplantation (FMT) can significantly improve treatment outcomes [2][4] - The bacterium is closely associated with various immune-related diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis, indicating its potential in disease prevention [2][4] Group 2: Technological Advancements - The company Shanenkan has developed AKK PROBIO, which demonstrates a comprehensive approach to immune damage repair, showcasing five core breakthroughs: balancing inflammatory factors, repairing immune organs, strengthening gut barriers, regulating gut microbiota, and stabilizing body weight [4][6] - The research team has established a robust evaluation system to assess the multifaceted effects of AKK PROBIO on immune health, marking a significant advancement from basic research to practical application [4][6] Group 3: Market Potential - Since 2019, Shanenkan has been a pioneer in AKK research in China, indicating a strong commitment to exploring the health benefits of this bacterium [6][7] - The multi-dimensional protective mechanisms of AKK PROBIO suggest its potential in preventing immune-related diseases and maintaining immune health in the general population, positioning it as a "guardian of gut microbiota" [6][7]